{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:08:22Z","timestamp":1793837302305,"version":"4.6.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chronic infection with HBV is responsible for &gt;50% of all hepatocellular cancer cases globally and disproportionately affects sub-Saharan African\u00a0(sSA) countries. Migration from these countries to Europe has increased substantially in recent years, posing unique challenges to health systems. The aim of this study was to carry out a community-based intervention to increase HBV screening, vaccination, and linkage to care among sSA migrants in Catalonia, Spain.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a prospective cohort study. Participants \u226518 years were offered community-based HBV screening between 20\/11\/20 and 21\/01\/22. Rapid HBV testing and blood sample collection utilizing plasma separation cards were carried out and linkage to care was offered to all participants. HBV vaccination and post-test counseling were performed at a second visit in the community. The main outcome was the odds of those with current HBV infection being successfully linked to hepatology. Rates of completing the care cascade of this model were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the present study, 444 people undergo screening, with 50.6% of participants showing evidence of past or current HBV infection, including an HBsAg prevalence of 9.2%. Migrants with current HBV infection exhibit 5.2 times higher odds of successful linkage to care compared to those in need of post-test counseling or vaccination. The study achieves a successful linkage to care rate of 72% for all participants, with specialist appointments arranged within 15.5 days.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>This community-based HBV screening program provides evidence of a successful model for identifying and providing care, including vaccination, to west African migrants at high risk of HBV infection who may otherwise not engage in care.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s43856-023-00420-8","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T09:03:09Z","timestamp":1702544589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Community-based screening enhances hepatitis B virus linkage to care among West African migrants in Spain"],"prefix":"10.1038","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0321-662X","authenticated-orcid":false,"given":"Camila A.","family":"Picchio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K.","family":"Nomah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Rando-Segura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Lens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Rodriguez","family":"Tajes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pamplona Portero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen L\u00f3pez","family":"Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"van Selm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4818-1722","authenticated-orcid":false,"given":"Marina","family":"MacKinnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia G.","family":"Araujo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Martr\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Rodr\u00edguez-Fr\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9618-2299","authenticated-orcid":false,"given":"Jeffrey V.","family":"Lazarus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"key":"420_CR1","unstructured":"World Health Organization. Global Hepatitis Report 2017. (accessed 10 Nov 2022); https:\/\/www.who.int\/publications\/i\/item\/9789241565455."},{"key":"420_CR2","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1200\/GO.20.00425","volume":"7","author":"VVPK Mukthinuthalapati","year":"2021","unstructured":"Mukthinuthalapati, V. V. P. K. et al. Hepatocellular carcinoma in sub-Saharan Africa. JCO Glob. Oncol. 7, 756\u2013766 (2021).","journal-title":"JCO Glob. Oncol."},{"key":"420_CR3","unstructured":"International Organization on Migration (IOM). World Migration Report 2022. (accessed 9 Nov 2022); https:\/\/publications.iom.int\/books\/world-migration-report-2022."},{"key":"420_CR4","unstructured":"European Commission. Statistics on Migration to Europe. (accessed 9 Nov 2022); https:\/\/ec.europa.eu\/info\/strategy\/priorities-2019-2024\/promoting-our-european-way-life\/statistics-migration-europe_en."},{"key":"420_CR5","unstructured":"Instituto Nacional de Estadistica. Cifras de poblaci\u00f3n a 1 de enero 2021. Estadisticas de migraciones, a\u00f1o 2020. (accessed 9 Nov 2022); https:\/\/www.ine.es\/prensa\/cp_e2021_p.pdf."},{"key":"420_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01885-0","volume":"11","author":"CA Picchio","year":"2021","unstructured":"Picchio, C. A. et al. Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review. Sci. Rep. 11, 24133 (2021).","journal-title":"Sci. Rep."},{"key":"420_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/20477724.2017.1281374","volume":"111","author":"D Mipatrini","year":"2017","unstructured":"Mipatrini, D. et al. Vaccinations in migrants and refugees: a challenge for European health systems. A systematic review of current scientific evidence. Pathog. Glob. Health 111, 59\u201368 (2017).","journal-title":"Pathog. Glob. Health"},{"key":"420_CR8","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1016\/S2468-2667(22)00174-8","volume":"7","author":"RF Baggaley","year":"2022","unstructured":"Baggaley, R. F. et al. Prevention and treatment of infectious diseases in migrants in Europe in the era of universal health coverage. Lancet Pub. Health 7, e876\u2013e884 (2022).","journal-title":"Lancet Pub. Health"},{"key":"420_CR9","doi-asserted-by":"publisher","first-page":"e286","DOI":"10.1016\/S2542-5196(21)00036-X","volume":"5","author":"A Dalmau-Bueno","year":"2021","unstructured":"Dalmau-Bueno, A. et al. Frequency of Health-care service use and severity of illness in undocumented migrants in Catalonia, Spain: a population-based, cross-sectional study. Lancet Planet. Health 5, e286\u2013e296 (2021).","journal-title":"Lancet Planet. Health"},{"key":"420_CR10","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1111\/jvh.13182","volume":"26","author":"MKL Mason","year":"2019","unstructured":"Mason, M. K. L. et al. Hepatitis B and C testing strategies in healthcare and community settings in the EU\/EEA: a systematic review. J. Viral Hepat. 26, 1431\u20131453 (2019).","journal-title":"J. Viral Hepat."},{"key":"420_CR11","unstructured":"World Health Organization. Global Health Sector Strategy (GHSS) on viral hepatitis, 2016-2021. (accessed 9 Nov 2022); https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/246177\/WHO-HIV-2016.06-eng.pdf."},{"key":"420_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-96350-3","volume":"11","author":"CA Picchio","year":"2021","unstructured":"Picchio, C. A. et al. A novel model of care for simplified testing of HBV in African communities during the COVID-19 pandemic in Spain. Sci. Rep. 11, 17063 (2021).","journal-title":"Sci. Rep."},{"key":"420_CR13","unstructured":"Instituto de Estadistica de Catalau\u00f1a (IDESCAT). xtranjeros con tarjeta de residencia. Por pa\u00eds de nacionalidad. Provincias. (accessed 8 Feb 2023); https:\/\/www.idescat.cat\/indicadors\/?id=aec&n=15250&lang=es."},{"key":"420_CR14","unstructured":"Raosoft sample size calculator. (accessed 14 September 2023); http:\/\/www.raosoft.com\/samplesize.html."},{"key":"420_CR15","unstructured":"World Health Organization. WHO prequalification of in vitro diagnostics- Public Report. WHO reference number: PQDx 0451-013-00. (Accessed 19 Dec 2022); https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/200123_pqdx_0451_013_00_determine_hbsag_2_final_pqpr_v2.pdf (January 2020)."},{"key":"420_CR16","unstructured":"Rando, A. et al. Evaluation of dried plasma spot on the cobas\u00ae plasma separation card as a sample type for hepatitis B virus load quantification on the cobas\u00ae 6800 system. FRI381 EASL International Liver Conference 2020. (accessed 29 Mar 2023). https:\/\/www.journal-of-hepatology.eu\/article\/S0168-8278(20)31643-3\/pdf."},{"key":"420_CR17","unstructured":"Rando, A. et al. Evaluation of the whole blood spot on plasma separation card as a sample type for serological screening for hepatitis B and hepatitis D infection. Abstract 7262 ECCMID Conference 2020."},{"key":"420_CR18","doi-asserted-by":"publisher","first-page":"114039","DOI":"10.1016\/j.jviromet.2020.114039","volume":"289","author":"JM Campreci\u00f3s","year":"2021","unstructured":"Campreci\u00f3s, J. M. et al. Reflex viral load testing in dried blood spots generated by plasma separation card allows the screening and diagnosis of chronic viral hepatitis. J. Virol. Methods 289, 114039 (2021).","journal-title":"J. Virol. Methods"},{"key":"420_CR19","doi-asserted-by":"publisher","unstructured":"Cui, F. et al. Global reporting of progress towards elimination of hepatitis B and hepatitis C. Lancet Gasroenterol. Hepatol. https:\/\/doi.org\/10.1016\/S2468-1253(22)00386-7 (2023).","DOI":"10.1016\/S2468-1253(22)00386-7"},{"key":"420_CR20","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/jvh.13182","volume":"26","author":"LKM Mason","year":"2019","unstructured":"Mason, L. K. M. et al. Hepatitis B and C testing strategies in healthcare and community settings in the EU\/EEA: a systematic review. J. Viral Hepat. 26, 1359\u20131501 (2019).","journal-title":"J. Viral Hepat."},{"key":"420_CR21","unstructured":"El Periodico. Estas son las listas de espera de los hospitales catalanes. (accessed 8 Feb 2023). https:\/\/www.elperiodico.com\/es\/sociedad\/20221014\/listas-espera-hospitales-catalanes-operaciones-pruebas-diagnosticas-77196400 (14 Oct 2022)."},{"key":"420_CR22","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1111\/liv.15327","volume":"42","author":"E Martr\u00f3","year":"2022","unstructured":"Martr\u00f3, E. et al. Pilot hepatitis C micro-elimination strategy in Pakistani migrants in Catalonia through a community intervention. Liver Int. 42, 1751\u20131761 (2022).","journal-title":"Liver Int."},{"key":"420_CR23","doi-asserted-by":"publisher","first-page":"101852","DOI":"10.1016\/j.clinre.2021.101852","volume":"46","author":"G Colucci","year":"2022","unstructured":"Colucci, G. et al. Italian migrants study: an HCV and HBV micro-elimination pilot project. Clin. Res. Hepatol. Gastroenterol. 46, 101852 (2022).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"420_CR24","unstructured":"World Health Organization (WHO). Guidelines on hepatitis B and C testing. (Geneva, 2017)."},{"key":"420_CR25","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","volume":"67","author":"European Association for the Study of the Liver (EASL","year":"2017","unstructured":"European Association for the Study of the Liver (EASL). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J. Hepatol. 67, 370\u2013398 (2017).","journal-title":"J. Hepatol."},{"key":"420_CR26","unstructured":"European Centre for Disease Prevention and Control (ECDC). Public health guidance on screening and vaccination for infectious diseases in newly arrived migrants within the EU\/EEA 2018. (accessed 22 Dec 2022); https:\/\/www.ecdc.europa.eu\/en\/publications-data\/public-health-guidance-screening-and-vaccination-infectious-diseases-newly."},{"key":"420_CR27","unstructured":"World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022\u20132030. (accessed 22 Dec 2022); https:\/\/www.who.int\/publications\/i\/item\/9789240053779."},{"key":"420_CR28","doi-asserted-by":"publisher","first-page":"E254","DOI":"10.1016\/S1473-3099(22)00066-4","volume":"22","author":"AF Crawshaw","year":"2022","unstructured":"Crawshaw, A. F. et al. Defining the determinants of vaccine uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review. Lancet Infect. Dis. 22, E254\u2013E266 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"420_CR29","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/clinchem\/hvab170","volume":"68","author":"G Colucci","year":"2022","unstructured":"Colucci, G. et al. Clinical evaluation of plasma separation cards as a tool to collect, store, and test blood samples for hepatitis B and C serological markers. Clin. Chem. 68, 214\u2013217 (2022).","journal-title":"Clin. Chem."},{"key":"420_CR30","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2471\/BLT.20.260919","volume":"99","author":"JU Kim","year":"2021","unstructured":"Kim, J. U., Ingiliz, P., Shimakawa, Y. & Lemoine, M. Improving care of migrants is key for viral hepatitis elimination in Europe. Bull. World Health Org. 99, 280\u2013286 (2021).","journal-title":"Bull. World Health Org."},{"key":"420_CR31","doi-asserted-by":"publisher","first-page":"647","DOI":"10.15585\/mmwr.mm6921a2","volume":"69","author":"J Young","year":"2020","unstructured":"Young, J. et al. Evaluation of a program to improve linkage to and retention in care among refugees with hepatitis B virus infection\u2014three U.S. Cities, 2006\u20132018. MMWR Morb. Mortal. Wkly Rep. 69, 647\u2013650 (2020).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"420_CR32","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1016\/j.jhep.2004.08.012","volume":"41","author":"MC Mostert","year":"2004","unstructured":"Mostert, M. C., Richardus, J. H. & de Man, R. A. Referral of chronic hepatitis B patients from primary to specialist care: making a simple guideline work. J. Hepatol. 41, 1026\u20131030 (2004).","journal-title":"J. Hepatol."},{"key":"420_CR33","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.3390\/cells9102233","volume":"9","author":"Y Xiao","year":"2020","unstructured":"Xiao, Y., Thompson, A. & Howell, J. Point-of-care tests for hepatitis B: an overview. Cells 9, 2233 (2020).","journal-title":"Cells"}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-023-00420-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-023-00420-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-023-00420-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T09:08:03Z","timestamp":1702544883000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-023-00420-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["420"],"URL":"https:\/\/doi.org\/10.1038\/s43856-023-00420-8","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"6 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: C.A.P., D.K.N., A.R.S., E.F., Lv.S., M.M., S.G.A. and F.R.F. have no competing interests to report. S.L. has received research grants from Gilead Sciences and speaker and travel fees from Gilead and Abbvie; M.B. has acted as an advisor for Gilead Sciences, GSK, Abbvie, and Roche Diagnostics; X.F. has acted as an advisor for Gilead Sciences and Abbvie; S.R.T. reports speaker fees from Gilead Sciences and Abbvie, outside the submitted work; J.P.P. has received speaker fees from Gilead Sciences and Abbvie; C.L.N. has received speaker fees from Gilead Sciences and Abbvie; E.M. has received lecture fees and research grants from Abbott GmbH & Co. K.G., Gilead Sciences, Cepheid and Abbvie, outside of the submitted work; J.V.L. acknowledges grants and speaker fees from AbbVie, Gilead Sciences, MSD, and Roche Diagnostics to his institution, speaker fees from Echosens, Janssen, Novo Nordisk, and ViiV, and consulting fees from Novavax, outside of the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"182"}}